{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:43:29Z","timestamp":1786373009738,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.2215\/cjn.11501210","type":"journal-article","created":{"date-parts":[[2011,8,11]],"date-time":"2011-08-11T23:16:28Z","timestamp":1313104588000},"page":"2280-2288","source":"Crossref","is-referenced-by-count":27,"title":["Decreases in PTH in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism"],"prefix":"10.2215","volume":"6","author":[{"given":"Tadao","family":"Akizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20230601","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"R2-25-20230601","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney"},{"key":"R3-25-20230601","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R4-25-20230601","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"R5-25-20230601","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1542-4758.2007.00190.x","article-title":"Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study","volume":"11","author":"Kimata","year":"2007","journal-title":"Hemodial Int"},{"key":"R6-25-20230601","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1744-9987.2007.00540.x","article-title":"Patient Registration Committee of the Japanese Society for Dialysis Therapy, Tokyo, Japan: Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan","volume":"12","author":"Nakai","year":"2008","journal-title":"Ther Apher Dial"},{"key":"R7-25-20230601","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R8-25-20230601","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"R10-25-20230601","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncpneph0977","article-title":"Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?","volume":"5","author":"Wetmore","year":"2009","journal-title":"Nat Clinc Pract Nephrol"},{"key":"R11-25-20230601","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1523-1755.2000.00819.x","article-title":"Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group","volume":"57","author":"Indridason","year":"2000","journal-title":"Kidney Int"},{"key":"R12-25-20230601","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: Vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"key":"R13-25-20230601","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"R14-25-20230601","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"R15-25-20230601","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","article-title":"Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"14","author":"Goodkin","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R18-25-20230601","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-25-20230601","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.04381206","article-title":"Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and design overview","volume":"2","author":"Chertow","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R20-25-20230601","first-page":"290","article-title":"Current management of secondary hyperparathyroidism: A multicenter observational study (COSMOS)","volume":"21","author":"Cannata-Andia","year":"2008","journal-title":"J Nephrol"},{"key":"R21-25-20230601","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"R22-25-20230601","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1744-9987.2010.00906.x","article-title":"Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D): Rationale and study design","volume":"15","author":"Fukuhara","year":"2011","journal-title":"Ther Apher Dial"},{"key":"R23-25-20230601","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000327654","article-title":"Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: Baseline data from the MBD-5D","volume":"33","author":"Fukagawa","year":"2011","journal-title":"Am J Nephrol"},{"key":"R24-25-20230601","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins","volume":"4","author":"Payne","year":"1973","journal-title":"BMJ"},{"key":"R25-25-20230601","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/aje\/kwi188","article-title":"Easy SAS calculations for risk or prevalence ratios and differences","volume":"162","author":"Spiegelman","year":"2005","journal-title":"Am J Epidemiol"},{"key":"R26-25-20230601","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1744-9987.2009.00789.x","article-title":"An overview of dialysis treatment in Japan (as of Dec. 31, 2007)","volume":"13","author":"Nakai","year":"2009","journal-title":"Ther Apher Dial"},{"key":"R28-25-20230601","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R30-25-20230601","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2215\/CJN.05241008","article-title":"Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006","volume":"4","author":"St Peter","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R31-25-20230601","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R32-25-20230601","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.01060308","article-title":"Consistent control of mineral and bone disorder in incident hemodialysis patients","volume":"3","author":"Danese","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R33-25-20230601","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1053\/j.ajkd.2005.08.013","article-title":"Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group: The Kidney Disease Outcomes Quality Initiative (K\/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association with mortality in dialysis patients","volume":"46","author":"Noordzij","year":"2005","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201109000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:10Z","timestamp":1786369270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201109000-00025"}},"subtitle":["Associations with Changing Practice Patterns"],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.11501210","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}